Zhitong Finance App News, Qianjin Pharmaceutical (600479.SH) issued an announcement. Recently, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., a subsidiary of the company, received “Drug Registration Certificates” for ferrous succinate tablets and escitalopram oxalate tablets (5mg, 10mg, 20mg) approved and issued by the State Drug Administration.

According to reports, ferrous succinate tablets were first developed by LABORATOIREX.O and marketed in France in 1997 to prevent and treat iron deficiency anemia. According to Moentropy Pharmaceutical data, the total sales of ferrous succinate tablets in the domestic medical market and retail market in 2025 was 456 million yuan.

Escitalopram is a single dextroscopic isomer of racecitalopram, a dicyclic hydrophthalate derivative. Escitalopram oxalate tablets are used to treat depression and treat panic disorder with or without agoraphobia. According to Moentropy Pharmaceutical data, the total sales volume of escitalopram oxalate tablets in the domestic medical market and retail market in 2025 was 2,341 billion yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.